Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kythera Doubles Down On Double Chins With Bayer Buyback

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech buys back rights to its own drug after attaining a more advantageous financial position and successful late-stage results.


Related Content

Kythera Faces Advisory Committee Meeting For Double Chin Drug
Deals Of The Week Looks At 2014 Takeout Targets
Kythera Readies NDA For Double Chin Drug ATX-101
A Pair Of Biotechs Bet On The IPO Market
More And Better Biotech IPOs, But Step-Ups Still Lag
Deals Of The Week: Pfizer/FoldRx, Takeda/Orexigen, Bayer/Kythera ...


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts